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Consortium for Blood Group Genes (CBGG): 
2008 report
G. A. Denomme, C.M. Westhoff, L. Castilho, and M.E. Reid, on behalf of the CBGG Members*
The Consortium for Blood Group Genes is a worldwide organiza-
tion whose goal is to have a vehicle to interact, establish guide-
lines, operate a proficiency program, and provide education for 
laboratories involved in DNA and RNA testing for the prediction 
of blood group, platelet, and neutrophil antigens.
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The Consortium for Blood Group Genes (CBGG) is a nonprofit organization whose mission is “To estab-lish guidelines, to provide education, and to provide 
a proficiency exchange for laboratories involved in DNA or 
RNA testing for the determination of blood group, platelet, 
and neutrophil antigens.” The consortium was established 
at the inaugural meeting on October 23, 2004, in Balti-
more, Maryland, by a group of people with scientific or in-
dustry experience and interest in the field. The consortium 
is coordinated by Marion Reid with assistance of country 
coordinators: Lilian Castilho for Brazil, Gregory Denomme 
(with Maryse St. Louis as successor in 2009) for Canada, 
and Connie Westhoff for the United States. All members are 
expected to interact and participate. New members are en-
couraged to refer to the previously published information 
for background and progress information.1–4 The exchange 
of information is mainly accomplished through electronic 
mailings, proficiency evaluation exercises, and a yearly 
meeting.
The CBGG Document
 The CBGG Document outlines the function of the CBGG. 
This document contains information on the structure, or-
ganizational rules and bylaws, regulatory compliance plan, 
preferred terminology, and progress on the working parties 
including proficiency exchange program, guidelines of prac-
tice, DNA repository, funding, forms and disclaimers, and 
proposed Web site. It is highly recommended that CBGG 
members refer to this document for the aforementioned 
duties and activities. Meetings are held annually, in part, 
for members to discuss outstanding issues and to provide 
the opportunity to give input and accept amendments to 
the document. The CBGG Document is distributed to mem-
bers and is available to nonmembers on request.
 
Template Disclaimers
 CBGG members continue to recognize the importance 
of appropriately worded reports of molecular analyses for 
both blood donors and transfusion recipients. Members 
continue to support the current recommendation that blood 
components should not be labeled with molecular test re-
sults as the sole means of antigen identification. Molecular 
data continue to be a source of information in the resolution 
of complex serologic problems, and are not intended as the 
sole means for patient transfusion management decisions.
Target Alleles
 The list of target alleles prepared by the CBGG after 
meeting in 2007 was adopted. The preferred current termi-
nology is listed in Table 1 of this report under the heading 
Target antigen (target allele). However, the final naming 
of alleles relies on the decision of the International Soci-
ety for Blood Transfusion. When referring to a particular 
single-nucleotide polymorphism, nucleotide changes fol-
low the designated position, e.g., 125G>A; intronic nucle-
otide changes represented in the lower case, e.g., –33t>c. 
The associated amino acid substitutions (not shown) flank 
the designated position, e.g., Pro103Ser or P103S. Because 
gene numbering systems vary, and to avoid ambiguity in 
the location of nucleotide changes, the CBGG has adopted 
GenBank gene reference sequences (RefSeqGene) and ref-
erence SNP numbers (rs#) for blood group genes and nucle-
otides (Table 1). These numbers provide the set of common 
references used to communicate or report molecular testing 
results.
Guidelines for Molecular Testing
 The CBGG has developed guidelines for free and gener-
al distribution. In 2007, the CBGG guidelines were shared 
with the AABB Molecular Testing Standards Program Unit 
(SPU). In addition, five CBGG members are committee 
members of the AABB Molecular Testing SPU, and one 
member (MER) holds liaison status with the committee. 
The AABB Standards for Molecular Testing for Red Cell, 
Platelet, and Neutrophil Antigens was published in 2008.5 
The intent of the CBGG guidelines is to maintain an inde-
pendent forum and voice for proposed molecular testing 
standards in ISO format for use by international laborato-
ries. The members will update, modify, or otherwise amend 
the CBGG guidelines by process of discussion and consen-
sus. The CBGG guidelines will not become standards as 
such to reflect the fact that the CBGG is not responsible for 
laboratory inspection or accreditation.
Report
* Full listing of  the members of  the CBGG can be found in the appendix.
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Proficiency Program
 An exchange of samples among several blood centers, 
transfusion services, and reference laboratories serves as 
one mechanism to evaluate proficiency in molecular test-
ing. The proficiency programs involve the sending out of a 
single sample (either DNA or whole blood) by a member 
in the spring and fall of each year. In the fall of 2008, the 
CBGG blood group program provided its first whole blood 
sample for proficiency exchange, which was coordinated 
through the Canadian Blood Services, Network Center for 
Applied Development (NetCAD) laboratory. Before any dis-
tribution, the target antigen must be tested by a PCR-based 
method and be confirmed by serology, with the additional 
caveat that the proficiency exercise will not involve rare al-
leles. A limited number of antithetical blood group antigens 
are evaluated, which are based on the assays performed by 
all participating members. As of spring 2008, the alleles are 
as follows: RHCE*E/RHCE*e, GYPB*S/GYPB*s, KEL*1/
KEL*2, FY*A/FY*B, FY*–33C/T GATA, and JK*A/JK*B. 
The cost of sample preparation and shipping the DNA 
sample is borne in turn by each submitting laboratory. To 
participate in the sample exchange, proficiency program 
members must agree to provide a sample for distribution 
in a subsequent year through a predetermined rotation. 
Although participation in the CBGG proficiency program 
mandates that samples are discarded after the results have 
been validated, proficiency program members must ensure 
they comply with regulatory bodies. Thus, before joining 
the proficiency exchange program and committing to sup-
ply a sample for the exchange, new members should address 
their institutional requirements on informed consent.
 To prevent communication errors because of different 
reporting mechanisms, a report form has been developed 
specifically for the CBGG proficiency program, a copy of 
which is contained in the CBGG 2008 Document. Commu-
nication of results between the submitting and testing labo-
ratories is done by using this form. Presently, proficiency 
reports for FY or GYPB*S/s should include appropriate 
disclaimers in the comment section for those laboratories 
that do not evaluate common modifying and silencing nu-
cleotide changes for these genes. A summary of the results 
from the participating laboratories for each proficiency ex-
ercise is compiled by the submitting laboratory and submit-
ted to the New York Blood Center for archival purposes.
 The proficiency evaluations for platelets and neutro-
phils are distributed to a specific group of members. 
Serologic confirmation is not mandated by this group owing 
to the lack of regulated antisera. The first exchange for plate-
let genotyping was coordinated by Vagner Castro (Platelet 
Immunology Laboratory of Hematology and Hemotherapy 
Center of the State University of Campinas, UNICAMP). 
This sample was previously genotyped by PCR-RFLP and 
PCR-SSP to the two HPA systems most frequently involved 
in platelet alloimmunization: HPA-1 and HPA-5.
Conclusions
 The CBGG is a self-help, not-for-profit organization 
designed as an interactive collaborative for members to 
learn from each other and to strive to achieve excellence in 
molecular testing of blood group, platelet, and neutrophil 
antigens. Anyone interested and willing to contribute intel-
lectually is welcome to join. To become a member contact 
Marion Reid (mreid@nybloodcenter.org), Lilian Castilho 
(castilho@unicamp.br), Maryse St. Louis (maryse.st-louis@
hema-quebec.qc.ca), Greg Denomme (greg.denomme@
bcw.edu), or Connie Westhoff (WesthoffC@usa.redcross.
org).
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Table 1. List of blood group target antigens and alleles









Control each nt analysis
with the three genotypic
classes when appropriate †




nt 1061ΔC (rs56392308) Many A/B alleles have been 
described, multiple targets are 
necessary for identification.



















nt 72 is the 3rd nt of codon 24
S (GPB*S)
s (GPB*s)
GYPB (NG_007483.1) nt 143T>C (rs7683365) Disclaimer required if null alleles not 
tested.
S silenced nt 230C>T
intron 5+5g>t





Exon 4 & 7
Ex 4 37 bp insert









Cw nt 122A>G †
Cx nt 106G>A †
V & VS nt 733C>G (rs1053361) †





















FY (NC_000001.9) nt 125G>A (rs12075)
Fyx nt 265C>T (rs34599082) †





















SC (NG_008749.1) nt 169G>A (rs56025238) †
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DO (NG_007477.1) nt 793A>G (rs11276)
Hy nt 323G>T (rs28362797)










LW (NG_007728.1) nt 308A>G †
Cromer (CR)
021





KN (NG_007481.1) nt 4681G>A (rs41274768)
McCa
McCb
nt 4768A>G (rs17047660) †
Sla
Vil





IN (NG_008937.1) nt 252C>G
OK (OK)
024
Oka OK (NG_007468.1) nt 274G>A †
Heterozygote not required
* NG_number.n represent the GenBank reference gene sequence (RefSeqGene) accession code for each blood group system gene.
# The rs number in brackets represents the GenBank SNP reference sequence (SNP rs) accession code for the given nucleotide (nt).
† Homozygous rare alleles are not required for molecular testing.
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Appendix   
Members of CBGG at end of 2008:
Coordinator:
Marion E. Reid, PhD
Laboratory of Immunochemistry and Laboratory
of Immunohematology
New York Blood Center
310 East 67th Street
New York, NY 10065
Country Coordinators:
Connie Westhoff, PhD
Molecular Blood Group and Platelet Antigen Testing Laboratory
American Red Cross-Penn-Jersey Region




1070, Avenue des Sciences-de-la-Vie
Quebec, Quebec G1V 5C3, Canada
Lilian Maria de Castilho, PhD
Laboratory of Immunohematology
Hemocentro-State University of Campinas (UNICAMP)
Rua Carlos Chagas 480 Barão Geraldo
Campinas, São Paulo, 13081-970, Brazil
Members:
Bai Yu, MD, PhD
Department of Pathology and Laboratory Medicine
University of Texas Health Science Center at Houston
6431 Fannin Street, MSB 2.222
Houston, TX 77030
Daniel B. Bellissimo, PhD
Molecular Diagnostics Laboratory
BloodCenter of Wisconsin










Hematology and Hemotherapy Center
Hemocentro-State University of Campinas (UNICAMP)
Rua Carlos Chagas 480 Barão Geraldo
Campinas, São Paulo, 13081-970, Brazil
Laura Cooling, MD
University of Michigan Hospitals
1500 East Medical Center Drive
Ann Arbor, MI 48109-0054
Ana Paula Cozac, MD
Centro Regional de Hemoterapia de Ribeirão Preto
Ribeirão Preto, S.P. CEP 14051-140, Brazil
Daniel de la Vega, PhD
Servicio de Medicina Transfusional
Hospital Italiano Garibaldi
Virasoro 1249 Rosario (2000)
Argentina




Blood Center of Wisconsin




New York Blood Center
310 East 67th Street
New York, NY 10065
Lakshmi K. Gaur, MSc, PhD
Puget Sound Blood Center
921 Terry Avenue
Seattle, WA 98104-1256
Ghazala P. Hashmi, PhD
Bioarray Solutions




New York Blood Center
310 East 67th Street
New York, NY 10065
Susan T. Johnson, MSTM, MT(ASCP)SBB
Manager, Immunohematology Services
BloodCenter of Wisconsin
638 North 18th Street
Milwaukee, WI 53233
Hallie Lee-Stroka
Department of Transfusion Medicine
Clinical Center
National Institutes of Health
10 Center Drive MSC 1184
Bethesda, MD 20892
Christine Lomas-Francis, MS, FIBMS
Immunohematology Laboratory
New York Blood Center
45-01 Vernon Blvd.








2424 West Erie Drive
Tempe, AZ 85282
Gandhi J. Manish, MD
Laboratory Medicine and Pathology
Mayo Clinic
200 First Street, S.W.
Rochester, MN 55905
Mariza A. Mota, PhD
Departamento de Hemoterapia
Hospital Israelita Albert Einstein
Av. Albert Einstein, 627 - 4° andar, Morumbi
São Paulo, SP CEP 05651-901 Brazil










Sandra Nance, MS, MT(ASCP)SBB
Technical Services
American Red Cross Penn-Jersey Region
700 Spring Garden Street
Philadelphia, PA 19123
Marcia Zago Novaretti, MD, PhD
Division of Immunohematology and Transfusion




Blood Centers of the Pacific
270 Masonic Avenue
San Francisco, CA 94118
Jordão Pellegrino, Jr.









20925 Crossroads Circle, Suite 200
Waukesha, WI 53186
Dawn M. Rumsey, ART(CSMLT)
PEPFAR Team, Global Development




Puget Sound Blood Center
921 Terry Avenue
Seattle, WA 98104-1256
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St. Paul, MN 55114
Antonio Sergio Torloni, MD
Mayo Clinic
13400 East Shea Boulevard
Scottsdale, AZ 85259
Sunitha Vege, MS
Molecular Blood Group and Platelet Antigen Testing Laboratory
American Red Cross
700 Spring Garden Street
Philadelphia, PA 19123
Rita Fontão Wendel
Instituto de Hemoterapia Sirio-Libanes
Rua D. Adma Jafet, 91 - 2 Andar
Sao Paulo, CEP 01308-050 Brazil
Mark Yazer, MD
RBC Serology Reference Laboratory
Centralized Transfusion Service
University of Pittsburgh





Center for Biologics Evaluation and Research
Office of Blood Research and Review
Division of Blood Applications
Food and Drug Administration






Free Classified Ads and Announcements  
Immunohematology will publish classified ads and announcements (SBB schools, meetings, symposia, etc.) 
without charge.  Deadlines for receipt of these items are as follows:
Deadlines
1st week in January for the March issue
1st week in April for the June issue
1st week in July for the September issue
1st week in October for the December issue
E-mail or fax these items to immuno@usa.redcross.org or (215) 451-2538.
For information concerning 
Immunohematology, Journal of Blood 
Group Serology and Education, or 
the Immunohematology Methods and 
Procedures manual, contact us by e-mail at 
immuno@usa.redcross.org
 
For information concerning the National 
Reference Laboratory for Blood Group 
Serology, including the American Rare 
Donor Program, please contact Sandra 
Nance, by phone at (215) 451-4362, by fax at 
(215) 451-2538, or by e-mail at snance@usa.
redcross.org
